medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
baxter phase busi mix prove durabl
crisi accompani underli momentum
model baxter prior guidanc withdrawn still
achiev multipl dynam drive ep
quarter revenu vs mse cc
organ repres pt momentum deceler baxter guid
cc growth late quarter march model high end
guidanc expect upsid baxter deliv strong quarter
adjust net posit impact relat demand
underli organ growth pt momentum deceler vs
growth pt decel respect quarter driven
deliveri vs mse well spectrum iq evo iq
global infus pump placement acut therapi vs mse
strong demand crrt prismax prismaflex adjust gross margin
slightli estim improv bp y/i benefit
strong top line favor manufactur variat adjust oper
margin modestli ahead mse ep vs
mse beat mainli driven top line vs mse tax due
dynam discuss strong signal hire plan
new employe global fill demand critic care product
segment focu
within acut therapi heighten covid-rel demand crrt
drove addit growth quarter go
forward strong demand crrt expect respons
baxter see demand strip suppli
deliveri organ growth pt momentum
deceler given strong comp baxter primarili benefit
demand iv solut mini-bag plu svp saw relat
demand drive addit revenu pt growth
compani see advanc purchas critic solut suppli
believ channel oversuppli dilig suggest
pump placement like lower signific larg custom
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
instal late last year expect pump demand replac
improv across quarter
invest need support demand necessari invest busi
along pension fx expens key dynam identifi
outlook may fulli appreci baxter never abl
provid initi guidanc addit baxter undertak number invest
initi total primarili
part previous announc suppli chain relat spend includ
increas capac product respons critic care product demand
hire worker global suppli employe critic ppe
revenu prove durabl earn like come
expect updat margin assumpt accordingli
forecast mid-teen oper margin sequenti
improv margin pressur
sever due anticip trough sale plan sequenc
invest spend addit non-op expens expect
increas primarili due ad interest expens tie
march bond offer lesser extent non-op incom chang
drive ep ep move lower
larg modest top line adjust impact invest initi
increas non-oper expens tie interest expens pension
unchang estim continu expect
baxter return normal discuss origin recoveri model
posit offset drive growth expect growth cc
slow acut impact declin cc
growth modest pick cc cc growth
challeng comp rais full year cc organ growth
respect demonstr durabl busi
model environ baxter six busi unit ex advanc
surgeri saw increas demand begin late march declin
elect surgeri cut demand advanc surgeri portfolio
expect continu throughout addit inform
detail review busi unit
thesi continu center around insul phase recoveri
model view baxter phase recoveri stori driven rel insul
busi model durabl posit offset balanc sheet flexibl
view hospit spend reprioritz critic care product crrt
iv solutions/infus pump driver strong demand
balanc maintain pt
segment perform segment strength rel broad base detail
major contributor
pharma vs mse increas organ basi growth
gener inject increas demand select pharmaceut use treat
patient increas demand us cyclo intern pharmaci
compound contribut inhal anesthesia sale neg impact
declin elect procedur go forward continu anticip
pressur inhal anesthesia off-set heighten demand dexm well
premix antibiot pain medic model lsd growth
acut therapi vs mse organ growth benefit
increas global demand baxter crrt pandem well
pt growth directli attribut relat demand expect
see strong demand model ldd organ growth
advanc surgeri vs mse see signific
neg impact follow gradual recoveri anticip
neg organ growth seprafilm close februari
contribut pt growth
deliveri vs mse organ growth
driven infus system go forward anticip msd
organ growth continu strong replac demand well benefit
roll-out novum iq canada us eua pend evo iq
renal vs mse grew organ perform quarter
driven hsd growth pd therapi global pull forward
acceler deliveri monthli patient china perform partial off-set
lower center hd sale reflect continu revaclear dialyz
suppli constraint baxter continu invest renal anticip
final rule white hous aakhi initi
nutrit vs mse increas organ basi us sale
directli benefit relat demand expect
nutrit underli growth modestli slow msd
compound busi neg impact lower diagnosi activ
pt reect multipl base case ebitda repres
discount larg cap peer set primarili given risk lrp miss compani
baxter current multipl reect
wamgr potenti
acceler medic deliveri
nutrit dynam stabil pipelin
baxter premium balanc sheet asset
risk low-return capit deploy
overst expect disciplin
approach involv repurchas
medic deliveri nutrit
headwind stabil
contribut low mid-singl digit growth
come year
growth leverag opportun
allow baxter reach low-doubl digit
earn growth level
includ acceler
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
baxter margin ramp faster anticip
assum compound-annual-growth-rate back
new product initi margin hit
higher expect guidanc
om/gm ratio
capit wacc return
diversifi faster growth end market
drive higher demand
deliveri nutrit product baxter
achiev organ sale growth
new product geograph expans
drive acceler margin continu
expand baxter execut tuck-in
medium size deal also buy back
baxter new product initi fail
deliv growth slow compound-annual-growth-rate
benet product mix fail materi
margin expans slow materi
result oper margin
strateg action fail occur
deliv wacc return
medic deliveri upsid drive
baxter expect new product sale
drive pt compound-annual-growth-rate
deploy balanc sheet
bp margin expans drive pt
china india
view explan region hierarchi
research highest favor quintil
crrt benet
acceler meaning
renal growth ahead expect driven
aakhi theranova
margin expans estim
disrupt surgeri nutrit
materi expect
potenti activ below- wacc
inabl gener oper leverag
inabl grow wamgr
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
million
sale
sale
sale
sale
st def tax asset disposit
current matur lt debt leas oblig
commit conting
oper
incom disc op net tax
depreci amort
realiz excess tax benefit stock issu employ benefit plan
net period pension benefit opeb cost
sale discontinu oper
infus product-rel charg
loss gain relat conting payment liabil
chang balanc sheet item
oper
invest
acquisit invest net
divestitur invest activ
invest
financ
issuanc debt
payment oblig
increas decreas st debt
dividend common stock
proce realiz excess tax benefit stock issu employe benefit plan
purchas treasuri stock issuanc equiti
financ
effect exchang rate chang
begin period balanc
end period balanc
